-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Arnold Pharma, an innovative global biopharmaceutical company focusing on the field of tumor treatment, recently announced that it will announce the pre-clinical version of anti-hTNFR2 (AN3025) at the American Association for Cancer Research (AACR) 2021 annual meeting in the form of an electronic poster.
The data and summary content have been published on the AACR official website
.
The AACR annual meeting will be held in the form of virtual meetings on April 10-15 and May 17-21, Eastern Time
The published research results are as follows:
Abstract/Poster Number: 1452
Title: AN3025: Immunostimulatory anti-hTNFR2 antibody with good anti-tumor activity?
Sub-venue category: drug research and development for the tumor microenvironment
The AN3025 antibody firstly uses the rabbit's immune system to generate initializing antibodies, then screens and purifies them using phage display technology, and then humanizes them by CDR transplantation
.
In order to evaluate the pharmacological properties and anti-tumor activity of the antibody, Arnold Pharma has carried out a series of early preclinical research trials
The above test results show that the AN3025 antibody shows extremely high affinity in binding to human TNFR2 and can block the interaction between TNFR2 and TNF
.
The antibody showed a certain promotion effect on the production of interferon-γ (IFN-γ) in the Treg/Teff co-culture test, and significantly inhibited the growth of MC38 tumors in the hTNFR2 mouse model alone administration test
“In pre-clinical research, the AN3025 project has proven its great potential in tumor control,” said Dr.
He Nanhai, head of Arnold Pharmaceuticals’ drug development.
“We will continue to advance this exciting project and look forward to its development.
Enter the clinical stage in the near future
.
"
About AN3025
AN3025 is a new type of humanized IgG1 anti-hTNFR2 antibody, currently in the preclinical development stage
.
The antibody binds to the extracellular domain of human cells TNFR2 with sub-nanomolar affinity, and prevents its ligand TNF from binding to TNFR2
About Arnold Pharma
Arnold Pharma is a clinical-stage global biopharmaceutical company focusing on the development of innovative oncology drugs
.
It has R&D and clinical operation centers in both China and the United States .
Arnold Pharma has established a competitive management team and built a unique drug development technology platform.
At the same time, it has established strategic partnerships with many top pharmaceutical companies in the world
.
Arnold Pharma is committed to becoming an innovative R&D company that creates "global new" oncology drugs, bringing more effective treatments to patients in China and even the world, and realizing the mission of turning cancer into a non-fatal disease and even curing
